NASDAQ$NKTX
Nkarta Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Nkarta reported financial results for the third quarter ended September 30, 2020.
Nkarta reported a net loss of $13.7 million, or $0.44 per share, for the third quarter of 2020. The company ended the quarter with $330.2 million in cash and cash equivalents.
- First patient dosed in clinical trial of NKX101 in acute myeloid leukemia and myelodysplastic syndromes.
- IND application for NKX019 expected to be filed in 1Q 2021.
- Ended third quarter 2020 with $330.2 million of cash and cash equivalents.
- Cash and cash equivalents are believed to be sufficient to fund operations into at least the second half of 2023.
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$115K
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023. The company expects cash and cash equivalents at December 31, 2020 to be in the range of $300 million to $310 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
+0.4%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.4%
Avg return
30 days after
61%
14 / 23 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.5% | -16.1% | — | |
| Q4 2025 | +0.9% | -0.9% | +37.1% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro